FindTrial
Sign In

Determination of Optimal Dose of Aspirin in Secondary Prevention of Cerebrovascular Diseases by Optical Aggregometry and comparing the results with manual method.

Determination of Optimal Dose of Aspirin in Secondary Prevention of Cerebrovascular Diseases by Optical Aggregometry and comparing the results with manual method.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/001224
Enrollment
116
Registered
2010-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Control Intervention1: Nil:

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects for platelet aggregation test should be resting, fasting and non-smoking. Stroke patient with ASA/Anticoagulant drugs or both. Healthy Controls for Comparison.

Exclusion criteria

Exclusion criteria: Patients : with Bleed, Haemorrhage will be excluded. For controls: no medication, no risk factors like HT,DM,IHD etc.

Design outcomes

Primary

MeasureTime frame
Aspirin in a dose of 150 mg seems to produce a significant inhibition of platelet aggregation, but the response is highly variable.Timepoint: Nil—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr. P. M. Dalal

Research Director, L.K.M.M.Trust Research Centre

pmdalal_in@yahoo.com02226568000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026